Payment overview · 2025
General Payments
$228.53
10 reported records · 4 companies
Healthcare provider profile · identity verified
Phillip Charles Teague, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUGARCREEK, OH · NPI 1770571069
Verified facts
What the public records show
CMS Open Payments records show Phillip Charles Teague, MD received $228.53 in general payments during 2025 across 10 reported records.
Boston Scientific Corporation accounted for 45.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $103.65 | 45.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.68 | 37.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.94 | 9.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.26 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $228.53 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $103.65 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.08 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 545 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 529 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 52 |
| Eliquis | Apixaban | 288 | 30 |
| Lisinopril | Lisinopril | 272 | 63 |
| Sertraline Hcl | Sertraline Hcl | 258 | 44 |
| Furosemide | Furosemide | 254 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 49 |
| Gabapentin | Gabapentin | 243 | 35 |
| Metformin Hcl | Metformin Hcl | 243 | 44 |
| Alprazolam | Alprazolam | 200 | 34 |
| Potassium Chloride | Potassium Chloride | 199 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 173 | 24 |
| Losartan Potassium | Losartan Potassium | 152 | 32 |
| Lactulose | Lactulose | 130 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 25 |
| Omeprazole | Omeprazole | 113 | 22 |
| Jardiance | Empagliflozin | 105 | 14 |
| Levetiracetam | Levetiracetam | 105 | 11 |
| Mirtazapine | Mirtazapine | 101 | 21 |
| Carvedilol | Carvedilol | 99 | 17 |
| Divalproex Sodium | Divalproex Sodium | 97 | 16 |
| Finasteride | Finasteride | 94 | 12 |
| Trazodone Hcl | Trazodone Hcl | 94 | 22 |
| Buspirone Hcl | Buspirone Hcl | 93 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 26 |
| Trulicity | Dulaglutide | 84 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 13 |
| Carbamazepine | Carbamazepine | 70 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 66 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 59 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 59 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 11 |
| Ezetimibe | Ezetimibe | 57 | suppressed |
| Famotidine | Famotidine | 57 | 16 |
| Olanzapine | Olanzapine | 57 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 55 | 11 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Spironolactone | Spironolactone | 51 | suppressed |
| Fenofibrate | Fenofibrate | 50 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 11 |
| Ozempic | Semaglutide | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 11 |
| Meloxicam | Meloxicam | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 22 |
| Risperidone | Risperidone | 43 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 42 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 17 |
| Mupirocin | Mupirocin | 39 | 19 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Cimetidine | Cimetidine | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 17 |
| Prednisone | Prednisone | 35 | 17 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Clotrimazole | Clotrimazole | 30 | suppressed |
| Nystatin | Nystatin | 30 | 20 |
| Allopurinol | Allopurinol | 29 | 11 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Phenytoin | Phenytoin | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Nyamyc | Nystatin | 21 | 12 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 13 |
| Fluconazole | Fluconazole | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Tetrabenazine | Tetrabenazine | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Loxapine | Loxapine Succinate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $228.53 · 10 records | Boston Scientific Corporation | AIRSUPRA, FARXIGA, INSPIRE, KISUNLA, WATCHMAN Access System | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error